Quercetin Phytosome® Chronic Fatigue Syndrome
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate whether a 3-month period of quercetin supplementation (500 mg of Quercetin Phytosome®) is useful in the treatment of chronic fatigue, as assessed by the Fatigue Impact Scale (FIS-40). Secondary end points are sleep assessment through Pittsburgh Sleep Quality Index (PSQI) and muscle performance assessment through the Short Physical Performance Battery (SPPB) and body composition assessment using DXA.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Intervention group
|
Dietary Supplement: Quercetin group
2 capsules a day of Quercetin Fitosoma® of 250 mg each
|
| Placebo Comparator: Placebo group
|
Dietary Supplement: Placebo group
2 tablets per day, white film-coated having the same appearance as Quercetin Fitosoma ® tablets.
|
Outcome Measures
Primary Outcome Measures
- chronic fatigue syndrome [At baseline and after 3 months]
The primary outcome is the change in self-reported fatigue scores assessed using the Fatigue Impact Scale (FIS-40)
Secondary Outcome Measures
- Sleep quality [At baseline and after 3 months]
Sleep disturbances are assessed using the 19-item self-administered Pittsburgh Sleep Quality Index (PSQI) questionnaire. Scores are obtained on each of the seven sleep quality domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, sleeping pills, and daytime dysfunction. Each component is rated from 0 to 3 (0 = no sleep problems and 3 = severe sleep problems). The overall PSQI score ranges from 0 to 21 points, with scores ≥5 indicating worse sleep quality
- Physical performance [At baseline and after 3 months]
Physical performance is assessed using the Short Physical Performance Battery test
- Body composition [At baseline and after 3 months]
Body composition is assessed using the dual X-Ray absorptiometry (DXA)
- Life quality [At baseline and after 3 months]
Quality of life is assessed using the Short-Form 12-Item Health Survey (SF-12), a short and generic measure of health status that reproduces the 2 summary scores of the SF-36, the summary of the physical component score and the summary score of the mental component, addressing eight health domains (physical functioning, physical role, body pain, general health, vitality, social functioning, emotional role and mental health)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
age ≥ 18 years old
-
confirmed diagnosis of chronic fatigue syndrome according to the 1994 CDC / Fukuda definition
Exclusion Criteria:
- patients with any active medical condition that explained chronic fatigue (untreated hypothyroidism, sleep apnea, narcolepsy, drug side effects and iron deficiency anemia), previous diagnosis not unequivocally resolved (chronic hepatitis, malignant tumors), past neuropsychiatric disorders o current (severe depressive disorder with psychotic or melancholy features, bipolar disorder, schizophrenia, delusional disorder, dementia, anorexia nervosa, bulimia nervosa) and participation in another clinical trial of the same or different nature within 30 days prior to inclusion in the study; failure to provide signed informed consent; consumption of certain drugs / supplements that could affect outcome measures in the past 90 days or whose discontinuation could be a significant problem, anticoagulant treatment, pregnancy or breastfeeding, smoking, alcohol or substance abuse, obesity (BMI> 30 kg / m2).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | l'Istituto di Riabilitazione e cura "Santa Margherita" di Pavia, Azienda di Servizi alla Persona (ASP). | Pavia | Italy | 27100 |
Sponsors and Collaborators
- Azienda di Servizi alla Persona di Pavia
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 0912/01072022